Enhancement of tumor radioresponse in vivo by gemcitabine

Cancer Research

Volumn 59, Issue 1, 1999, Pages 107-114

  Milas, Luka ^a   Fujii, Takashi ^a,b   Hunter, Nancy ^a   Elshaikh, Mohamed ^c   Mason, Kathy ^a   Plunkett, William ^a   Ang, K Kian ^a   Hittelman, Walter ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE S PHASE; CONTROLLED STUDY; CYTOSTASIS; DNA SYNTHESIS INHIBITION; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; TUMOR GROWTH;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL DIVISION; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DNA REPLICATION; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; NEOPLASMS, EXPERIMENTAL; RADIATION-SENSITIZING AGENTS;

EID: 0032948219     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Cox, J. D., Pajak, T. F., Marcial, V., Hanks, G. E., Mohiuddin, M., Fu, K. K., Byhardt, R. W., and Rubin, P. Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: Preliminary Report of the Radiation Therapy Oncology Group Protocol 83-13. Int. J. Radiat. Oncol. Biol. Phys., 18: 515-521, 1990.
2. Vokes, E. E., Weichselbaum, R., Lippman, S. M., and Hong, W. K. Head and neck cancer. N. Engl. J. Med., 328: 184-194, 1993.
3. Taylor, S. G., Murthy, A. K., Vannetzel, J-M., Colin, P., Dray, M., Caldarelli, D. D., Short, S., Vokes, E., Showel, J. L., Hutchinson, J. C., Witt, T. R., Griem, K. L., Hartsell, W. F., Kies, M. S., Millal, B., Rebischung, J-L., Coupez, D. J., Desphieux, J-L., Bobon, S., and LePajolec, C. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J. Clin. Oncol., 12: 385-395, 1994.
4. El-Sayed, S., and Nelson, N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: a meta-analysis of prospective and randomized trials. J. Clin Oncol., 14: 838-847, 1996.
5. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N. Engl. J. Med., 324: 1685-1690, 1991.
6. Crissman, J. D., Pajak, T. F., Zarbo, R. J., Marcial, V. A., and Al-Sarraf, M. Improved survival to combined cisplatin and radiation in nonkeratinizing squamous cell carcinomas of the head and neck. An RTOG study of 114 advanced stage tumors. Cancer (Phila.), 59, 1391-1397, 1987.
7. Marcial, V. A., Pajak, T. F., Mohiuddin, M., Cooper, J. S., Al-Sarraf, M., Mowry, P. A., Curran, W., Crissman, J., Rodriguez, M., and Velez-Garcia, E. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinomas of the head and neck. Long-term results of the Radiation Therapy Oncology Group Study 81-17. Cancer (Phila.), 66, 1861-1868, 1990.
8. Lo, T. C., Wiley, A. L.. Ansfield, F. J., Brandenburg, J. H., Davis, H. L. J., Gollin, F. F., Johnson, R. O., Ramirez, G., and Vermund, H. Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. Am. J. Roentgenol., 126: 229-235, 1976.
9. Gollin, F. F., Anfield, F. J., Brandenburg, J. H., Ramirez, G., and Vermund, H. Combined therapy in advanced head and neck cancer: a randomized study. Am. J. Roentgenol. Radium Ther. Nucl. Med., 114: 83-88, 1972.
10. Cachin, Y., Jortay, A., and Sancho, H. Preliminary results of a randomized E. O. R. T. C. study comparing radiotherapy and concomitant bleomycin to radiotherapy alone in epidermoid carcinomas of the oropharynx. Eur. J. Cancer. 13: 1389-1395, 1977.
11. Gupta, N. K., Pointon, R. C., and Wilkinson, P. M. A randomized clinical trial to contrast radiotherapy and radiotherapy and methotrexate given synchronously in head and neck cancer. Clin. Radiol., 38: 575-581. 1987.
12. Weissberg, J. B., Song, V. H., Papac, R. J., Sasaki, C., Fischer, D. B., Lawrence, R., Rockwell, S., Sartorelli, A. C., and Fischer, J. J. Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer Int. J. Radiat. Oncol. Biol. Phys., 17: 3-9, 1989.
13. McGinn, C. J., Shewach, D. S., and Lawrence, T. S. Review. Radiosensitizing nucleosides. J. Natl. Cancer Inst., 88: 1193-1203, 1996.
14. Gregoire, V., and Hittelman, W. N. Nucleoside analogs as radiosensitizing agents. In: B. D. Cheson, M. J. Keating, and W. Plunkett (eds.), Nucleoside Analogs in Cancer Therapy, pp. 315-358. New York: Marcel Dekker, Inc., 1997.
15. Catapano, C. V., Perrino, F. W., and Fernandes, D. J. Primer RNA chain termination induced by 9-β-D-arabinofuranosyl-2-fluoradenine 5′-triphosphate, J. Biol. Chem., 268: 7179-7185, 1993.
16. Huang, P., Chubb, S., and Plunkett, W. Termination of DNA synthesis by 9-β-o- arabinofuranosyl-2-fluoroadenine: a mechanism for cytotoxicity. J. Biol. Chem., 265: 16617-16625, 1990.
17. Tseng, W. C., Derse, D., Cheng, Y. C., Brockman, R. W., and Bennett, L. L., Jr. In vitro biological activity of 9-β-arabinofuranosyl-2-fluoroadenosine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol. Pharmacol., 21: 474-477, 1982.
18. Yang, S. W., Huang, P., Plunkett, W., Becker, F. F., and Chan, J. Y. H. Dual mode of inhibition of purified DNA ligase [ from human cells by 9-β-D-arabinofuranosyl-2-fluoroadenosine. J. Biol. Chem., 267: 2345-2349, 1992.
19. Gregoire, V., Hunter, N., Milas, L., Brock, W. A., Plunkett, W., and Hittelman, W. N. Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine. Cancer Res., 54: 468-474, 1994.
20. Gregoire, V., Hunter, N., Brock, W. A., Milas, L., Plunkett, W., and Hittelman, W. N. Fludarabine improves the therapeutic ratio of radiotherapy in mouse tumors after single dose irradiation. Int. J. Radiat. Oncol. Biol. Phys., 30: 363-371, 1994
21. Gregoire, V., Hunter, N. R., Brock, W. A., Hittelman, W. N., Plunkett, W., and Milas, L. Improvement in the therapeutic ratio of radiotherapy for a murine sarcoma by indomethacin plus fludarabine. Radiat. Res., 146: 548-553, 1996.
22. Gregoire, V., Van, N. T., Brock, W. A., Milas, L., Plunkett, W., and Hittelman, W. N. The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo. Cancer Res., 54: 6201-6209, 1994.
23. Gregoire, V., Ruifrok, A. C. C., Price, R. E., Brock, W. A., Hittelman, W. N., Plunkett, W. K., and Ang, K. K. Effect of intra-peritoneal fludarabine administration on rat spinal cord tolerance to fractionated irradiations. Radiother. Oncol., 36: 50-55, 1995.
24. Hanauske, A-R., and Von Hoff, D. D. Clinical development of fludarabine, In: B. D. Cheson, M. J. Keating, and W. Plunkett (eds.). Nucleoside Analogs in Cancer Therapy, pp. 113-158. New York: Marcel Dekker, Inc., 1997.
25. Hertel, L. W., Kroin, J. S., Misner, J. W., and Tustin, J. M. Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2-difluoro-D-ribofuranosyl nucleotides. J. Org. Chem., 53: 2406-2409, 1988.
26. Heinemann, V., Hertel, L. W., Grindey, G. B., and Plunkett, W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res., 48: 4024-4031, 1988.
27. Plunkett, W., Gandhi, V., Chubb, S., Nowak, B., Heinemann, V., Mineishi, S., Sen, A., Hertel, L. W., and Grindey, G. B. 2′,2′-Difluorodeoxycytidine metabolism and mechanism of action in human leukemia cells. Nucleosides Nucleotides, 8: 775-785, 1989.
28. Plunkett, W., Huang, P., Xu, Y-Z., Heinemann, V., Grunewald, R., and Gandhi, V. Gemcitabine: metabolism, mechanisms of actions, and self-potentiation. Semin. Oncol., 22 (Suppl. 11): 3-10, 1995.
29. Plunkett, W., Huang, P., and Gandhi, V. Preclinical characteristics of gemcitabine. Anti-Cancer Drugs, 6 (Suppl. 6): 7-13, 1995.
30. Hertel, L. W., Boder, G. B., Kroin, J. S., Rinzel, S. M., Poore, G. A., Todd, G. C., and Grindey, G. B. Evaluation of antitumor activity of a (2′,2′-difluoro-2′-deoxycytidine). Cancer Res., 50: 4417-4422, 1990.
31. Braakhuis, B. J., van Dongem, A. M. S., Vermorken, J. B., and Snow, G. B. Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (gemcitabine) against head and neck cancer. Cancer Res., 51: 211-214, 1991.
32. Braakhuis, B. J. M., Ruiz van Haperen, V. W. T., Welters, M J. P., and Peters, G. J. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur. J. Cancer, 31A: 2335-2340, 1995.
33. Kim, J. H., Alfieri, A. A., Kim, S. H., and Fuks, Z. The potentiation of radiation response on murine tumors by fludarabine phosphate. Cancer Lett., 31: 69-76, 1986.
34. Guchelaar, H. J., Richel, D. J., and van Knapen, A. Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer Treat. Rev., 22: 15-31, 1996.
35. Rockwell, S., and Grindey, G. B. Effect of 2′,2′-difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro. Oncol. Res., 4: 151-155, 1992.
36. Shewach, D. S., Hahn, T. M., Chang, E., Hertel, L. W., and Lawrence, T. S. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res., 54: 3218-3223, 1994.
37. Lawrence, T. S., Chang, E. Y., Hahn, T. M., Hertel, L. W., and Shewach, D. S. Radiosensitization of pancreatic cancer cells by 2′,2′difluoro-2′-deoxycytidine. Int. J. Radiat. Oncol. Biol. Phys., 34: 867-872, 1996.
38. Lawrence, T. S., Eisbruch, A., and Shewach, D. S. Gemcitabine-mediated radiosensitization. Semin. Oncol., 24 (Suppl. 7): S7-24-S7-28, 1997.
39. Huang, N. J., and Hittelman, W. N., Transient inhibition of chromosome damage repair after ionizing radiation by gemcitabine. Proc. Am. Assoc. Cancer Res., 36: 612, 1995.
40. Joschko, M. A., Webster, L. K., Groves, J., Yuen, K., Palatsides, M., Ball, D. L., and Millward, M. J. Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model. Radiat. Oncol. Invest., 5, 62-71, 1997.
41. Milas, L., Hunter, N., Mason, K., and Withers, H. R. Immunological resistance to pulmonary metastases in C3Hf/Bu mice bearing syngeneic fibrosarcoma of different sizes. Cancer Res., 34: 61-71, 1974.
42. Milas, L., Hunter, N. R., Mason, K. A., Kurdoglu, B., and Peters, L. J. Enhancement of tumor radioresponse of a murine mammary carcinoma by taxol. Cancer Res., 54: 3506-3510, 1994.
43. Milas, L., Hunter, N. R., Mason, K. A., Milross, C. G., Saito, Y., and Peters, L. J. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res, 55: 3564-3568, 1995.